Table 1 Baseline characteristics of the study population (n = 2211) compared to baseline characteristics of participants not included in this study (n = 502)
Study population n = 2211 | Not includedan = 502 | ||||
|---|---|---|---|---|---|
Baseline characteristics | n | % | n | % | p-valueb |
Age at interview: years (median, IQR) | 82.1 (78.8; 86.5) | 82.6 (79.2; 87.3) | 0.044 | ||
Baseline GARS (median, IQR) | 31 (24; 41) | 34 (25; 43) | 0.006 | ||
Sex | |||||
Male | 707 | 32.0 | 150 | 29.9 | 0.362 |
Female | 1504 | 68.0 | 352 | 70.1 | |
Polypharmacy | n = 501 | ||||
< 4 per day | 710 | 32.1 | 185 | 36.9 | 0.039 |
4 or more per day | 1501 | 67.9 | 316 | 63.1 | |
Multimorbidity | |||||
Yes (> 1 chronic disease) | 2011 | 91.0 | 458 | 91.2 | 0.843 |
No | 200 | 9.0 | 44 | 8.8 | |
Living situation | n = 501 | ||||
Independent, alone/with others | 1985 | 89.8 | 429 | 85.6 | 0.007 |
Home for older persons | 226 | 10.2 | 72 | 14.4 | |
GP opinion on vulnerability | n = 323 | ||||
Not vulnerable | 894 | 40.4 | 93 | 28.8 | < 0.001 |
Possibly vulnerable | 617 | 27.9 | 96 | 29.7 | |
Vulnerable | 700 | 31.7 | 134 | 41.5 | |
ISCOPE-score on ISCOPE screening questionnaire | |||||
0 (no domain with problems) | 198 | 9.0 | 49 | 9.8 | 0.099 |
1 (1 domain with problems) | 183 | 8.3 | 34 | 6.8 | |
2 (2 domains with problems) | 614 | 27.8 | 119 | 23.7 | |
3 (3 domains with problems) | 843 | 38.1 | 195 | 38.8 | |
4 (4 domains with problems) | 373 | 16.9 | 105 | 20.9 | |